Mark Goldsmith sells shares at Revolution Medicines (NASDAQ: RVMD)

Rhea-AI Filing Summary

Revolution Medicines reported insider sales of Common Stock by Mark A. Goldsmith. The filing lists a sale of 15,394 shares on 12/16/2025 for $1,182,525.52 and three sales on 03/02/2026 of 3,000 shares for $303,792.60, 3,000 shares for $303,984.90, and 30,000 shares for $3,036,576.00.

The filing also lists restricted stock unit grants dated 03/01/2022 (3,488 shares), 03/01/2023 (3,488 shares), 03/01/2024 (3,018 shares), and 03/01/2025 (3,267 shares) under issuer grants.

Insights

Insider Transactions Analyst

Routine Form 144 disclosure showing multiple dispositions by a reporting person.

The filing records open-market or private dispositions of Common Stock by Mark A. Goldsmith, with dated sales on 12/16/2025 and 03/02/2026

These entries list share counts and gross proceeds per trade. The aggregate or motive is not stated; the listed restricted stock unit grants are separate compensation items dated 03/01/2022–03/01/2025.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE Financial Corporation 3 Edison Drive Alpharetta GA 30005	13261	1320662.99	198173397	03/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/01/2022	Restricted stock unit grant	Issuer			3488	03/01/2022	Services rendered
Common Stock	03/01/2023	Restricted stock unit grant	Issuer			3488	03/01/2023	Services rendered
Common Stock	03/01/2024	Restricted stock unit grant	Issuer			3018	03/01/2024	Services rendered
Common Stock	03/01/2025	Restricted stock unit grant	Issuer			3267	03/01/2025	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark A. Goldsmith c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City KY 94063	Common Stock	12/16/2025	15394	1182525.52
Mark A. Goldsmith c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	03/02/2026	3000	303792.60
Mark A. Goldsmith c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	03/02/2026	3000	303984.90
Mark A. Goldsmith c/o Revolution Medicines, Inc. 700 Saginaw Drive Redwood City CA 94063	Common Stock	03/02/2026	30000	3036576.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What insider sales did Mark A. Goldsmith report for RVMD?

He reported sales of 15,394 shares on 12/16/2025 for $1,182,525.52 and three sales on 03/02/2026 totaling listed proceeds of $3,644,353.50 across 3,000, 3,000, and 30,000 share transactions.

Do the filings show restricted stock unit grants for Revolution Medicines (RVMD)?

Yes. The filing lists RSU grants dated 03/01/2022 (3,488), 03/01/2023 (3,488), 03/01/2024 (3,018), and 03/01/2025 (3,267) described as issuer grants for services rendered.

Are the sale prices per share shown in the Form 144 excerpt for RVMD?

Yes. Each sale row pairs shares with gross proceeds allowing implied per‑share prices: for example, 15,394 shares for $1,182,525.52 and 30,000 shares for $3,036,576.00, as listed in the filing excerpt.

Does the Form 144 state why the insider sold shares?

No. The excerpt lists trade dates, share counts, and proceeds but does not provide a reason or indicate whether transactions were pursuant to a trading plan or for liquidity purposes.